1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search results consecutively by pressing the navigational buttons
(
<
1 of
12
>).
Within the text the search result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
[...] growth and contributes to malnutrition, causing learning disabilities and anemia in children. Praziquantel, which was developed by Merck in the 1970s as part of a research collaboration, is the only active ingredient to treat all forms of schistosomiasis and is a well-tolerated drug. Since 1983, it has been on the Model List of Essential medicines published by the World Health Organization (WHO). Managing and monitoring In 2007, we launched the Merck Praziquantel Donation Program (MPDP) in partnership with WHO. This project was originally intended to run for a period of 10 years, but Merck has decided to continue the fight until the parasitic disease [...]
[...] as well as the University of Makerere in Uganda. We are also a leading partner of the Pediatric Praziquantel Consortium . Through the Global Health Innovation Platform, Merck Serono promotes and sponsors educational programs. Some examples of this include grants for post-doctoral fellowships at the AiBST in Zimbabwe and grants for healthcare worker disease awareness at the University of Namibia. Through these efforts, we are striving to help build capacities in endemic countries. Additionally, Merck Serono participates in international fellowship programs that host post-docs from developing countries. The post-docs are trained on clinical operations practices and [...]
[...] including post-clinical trial access to study drugs and issues arising from the development of praziquantel for small children, as well as the opportunities and bioethical implications of biosimilars. Access to study drugs post trial is a commitment laid out in several ethical guidance documents, such as the Declaration of Helsinki . These state that if a study drug has shown itself to be beneficial, safe and in line with local requirements, it should continue to be available to trial participants after the clinical trial, which is what the MBAP has recommended. If the drug is commercially available, the patient will be switched to the marketed drug. If the drug is [...]
[...] Health Organization (WHO) in the fight against schistosomiasis in Africa. We have been donating praziquantel tablets to WHO with the common aim of eliminating the disease in Africa. To date, Merck has donated more than 200 million tablets to WHO, and more than 54 million patients have been treated, primarily including children. Merck has pledged to increase the number of tablets donated to up to 250 million per year starting in 2016. This donation, worth around USD 23 million per annum, will enable 100 million children to be treated annually. At the end of 2014, Merck called for various NTD constituencies to form the Global Schistosomiasis Alliance in order to help [...]
[...] Legend: Achieved In progress Not achieved New goal Society Goals: Fighting schistosomiasis with praziquantel Goal Action By? Status in 2013 and 2014 Status Eliminate schistosomiasis in African school children Provide tablets containing praziquantel free of charge to treat school children in Africa Ongoing Since 2007, more than 50 million patients have been treated, primarily school-aged children. Incrementally increase annual tablet donation by a factor of ten, to up to 250 million End of 2016 In 2014, we produced around 75 million tablets, of which more than 72 million were supplied to 20 African countries by the year's end, a collaborative effort with the World [...]
